Lonza Partners with Vineti Across its Cell and Gene Therapy Manufacturing Network to Optimize 'Vein-to-Vein' Delivery Service

- Vineti and Lonza as preferred partners, respectively for patient tissue tracking and contract development and manufacturing services in cell and gene therapy
- Unique partnership comprises fully integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s proprietary solutions including MODA-ES™.
- Lonza’s global cell & gene therapy manufacturing network provides worldwide access to cell and gene therapeutic technologies for customers to serve patients globally
- Vineti’s supply chain orchestration (SCO) platform enables real-time end-to-end connection between manufacturing and points of care while optimizing manufacturing capacity management.

Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:

“Our customers and their patients are at the heart of this partnership. With Vineti’s integrated software platforms, specifically designed to support cell and gene therapies, we have a highly scalable solution both geographically and in volume of output that takes us right where we want to be. As our customers move towards commercialization with increasing patient population sizes, they need reliable, fast and efficient technologies and infrastructures to handle seamlessly the collection, process and delivery of their therapies. This is what we aim to achieve with this partnership. Our customers will now also be able to better leverage our global manufacturing network and the centers that will provide their therapy through a well-orchestrated system which encompasses all the modalities of cell and gene therapy. We will continue to challenge ourselves to serve our customers better in this growing field, now and in the future.”

Quote from Amy DuRoss, CEO and Co-founder, Vineti:

“We’re very honored to have been selected as Lonza’s preferred supply chain orchestration partner,” said Amy DuRoss, CEO and Co-founder of Vineti. “Vineti and Lonza have a shared vision to grow, scale, and standardize the production and operations of cell and gene therapy worldwide. We’re very excited to serve biopharmaceutical partners together and to help open up patient access to these therapies more than ever before.”
Basel, Switzerland and San Francisco, CA, USA, 17 July 2019 – Lonza and Vineti announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, both Lonza and Vineti become preferred partners, respectively for patient tissue tracking and for contract development and manufacturing services in cell and gene therapy.

The unique partnership comprises a fully integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s proprietary solutions such as MODA-ES™. With the goal of seamless service for Lonza's customers and their patients, Lonza and its partners will work to remove the supply chain hurdles faced by developers of personalized therapeutics - including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines - as they prepare for the commercial launch of their therapies.

The Vineti supply chain orchestration (SCO) platform, the only independent solution known today to serve commercial cell & gene therapy products, will help Lonza's customers to keep a real-time end-to-end connection between Lonza and the points of care that prescribe their therapies. Together, the Lonza-Vineti solution will seek to provide biopharmaceutical developers with a pre-integrated SCO and manufacturing system that will offer digital, optimized end-to-end traceability and control. The partnership aims to establish faster, simpler operations and scale for cell and gene therapies, and to reduce the time that biopharmaceutical developers need to spend evaluating, implementing, and validating different systems. The partnership will also be working to provide this integrated system worldwide, using Lonza's global manufacturing presence and Vineti's ever-expanding network of leading medical centers. The Lonza-Vineti integrated solution will include Lonza’s proprietary solutions such as MODA-ES™, a next-generation electronic batch record execution solution that offers specific functionalities for cell and gene therapies manufacturing.

About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
About Vineti
Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers worldwide in 2019, on behalf of multiple biopharmaceutical partners.

Lonza Contact Details
Dr. Kristin Koehler
Investor Relations Officer
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

Dr. Sanna Fowler
Head of Public Relations
Lonza Pharma & Biotech
Tel +41 61 316 8929
sanna.fowler@lonza.com

Vineti Contact Details
Joseph Salerno
Director, PR and Scientific Communications
HDMZ, Inc.
joseph.salerno@hdmz.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.